EMAIL THIS PAGE TO A FRIEND

Environmental science & technology

Exposure to mutagenic disinfection byproducts leads to increase of antibiotic resistance in Pseudomonas aeruginosa.


PMID 24933271

Abstract

Bacterial antibiotic resistance (BAR) in drinking water has become a global issue because of its risks on the public health. Usually, the antibiotic concentrations in drinking water are too low to select antibiotic resistant strains effectively, suggesting that factors other than antibiotics would contribute to the emergence of BAR. In the current study, the impacts of mutagenic disinfection byproducts (DBPs) on BAR were explored, using four typical DBPs: dibromoacetic acid, dichloroacetonitrile, potassium bromate, and 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX). After exposure to DBPs, resistances to 10 individual antibiotics and multiple antibiotics were both raised by various levels, norfloxacin and polymycin B resistances were enhanced even greater than 10-fold compared with control. MX increased the resistance most observably in the selected DBPs, which was consistent with its mutagenic activity. The resistant mutants showed hereditary stability during 5-day culturing. The increase of BAR was caused by the mutagenic activities of DBPs, since mutation frequency declined by adding ROS scavenger. Mutagenesis was further confirmed by sequencing of the related genes. Our study indicated that mutagenic activities of the selected DBPs could induce antibiotic resistance, even multidrug resistance, which may partially explain the lack of agreement between BAR and antibiotic levels in drinking water.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

C1613 Carbenicillin, Ready Made Solution, 100 mg/mL in ethanol/water, 0.2 μm filtered
C17H18N2O6S
C9742
Clarithromycin, ≥95% (HPLC)
C38H69NO13
PHR1038
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
C38H69NO13
Y0000320
Clarithromycin, European Pharmacopoeia (EP) Reference Standard
C38H69NO13
1134379
Clarithromycin, United States Pharmacopeia (USP) Reference Standard
C38H69NO13
A3487
Clarithromycin, ≥98% (HPLC)
C38H69NO13
Y0000321
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
C38H69NO13
1134390
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
C38H69NO13
242357
Dibromoacetic acid, 97%
C2H2Br2O2
442551
Dibromoacetic acid, analytical standard
C2H2Br2O2
125954
Dichloroacetonitrile, 98%
C2HCl2N
442560
Dichloroacetonitrile, analytical standard
C2HCl2N
15821 Klebsiella Selective Supplement, for microbiology
C17H18N2O6S
N9890
Norfloxacin, analytical standard, ≥98% (TLC)
C16H18FN3O3
33899
Norfloxacin, VETRANAL, analytical standard
C16H18FN3O3
N1230000
Norfloxacin, European Pharmacopoeia (EP) Reference Standard
C16H18FN3O3
Y0001301
Norfloxacin for peak identification, European Pharmacopoeia (EP) Reference Standard
C16H18FN3O3
Y0001015
Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard
C16H18FN3O3
60085
Potassium bromate, puriss. p.a., ACS reagent, ≥99.8% (dried material, RT)
BrKO3
309087
Potassium bromate, ACS reagent, ≥99.8%
BrKO3
224855
Potassium bromate, ReagentPlus®, ≥99%
BrKO3